132 related articles for article (PubMed ID: 12657913)
1. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
[TBL] [Abstract][Full Text] [Related]
2. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y
Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320
[TBL] [Abstract][Full Text] [Related]
3. No interaction between desipramine and bromperidol.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
[TBL] [Abstract][Full Text] [Related]
4. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
[TBL] [Abstract][Full Text] [Related]
5. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
[TBL] [Abstract][Full Text] [Related]
6. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K
Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256
[TBL] [Abstract][Full Text] [Related]
7. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
[TBL] [Abstract][Full Text] [Related]
8. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
[TBL] [Abstract][Full Text] [Related]
10. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Furukori H
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
[TBL] [Abstract][Full Text] [Related]
11. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
12. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y
Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389
[TBL] [Abstract][Full Text] [Related]
13. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
[TBL] [Abstract][Full Text] [Related]
14. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
[TBL] [Abstract][Full Text] [Related]
16. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
18. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
19. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
[TBL] [Abstract][Full Text] [Related]
20. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
